Clearmind Medicine (XCNQ:CMND) Total Payout Yield % : -76.61 (As of May. 12, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Clearmind Medicine Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Clearmind Medicine's current Total Payout Yield % is -76.61%.

Clearmind Medicine Total Payout Yield % Historical Data

The historical data trend for Clearmind Medicine's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Total Payout Yield % Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Total Payout Yield %

Get a 7-Day Free Trial

-16.67

-20.02

-5.35

-403.22

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Payout Yield %	Get a 7-Day Free Trial															-265.13	-46.79	-23.60	-204.90	-

Competitive Comparison of Clearmind Medicine's Total Payout Yield %

For the Biotechnology subindustry, Clearmind Medicine's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Total Payout Yield % falls into.

Clearmind Medicine Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Clearmind Medicine's Total Payout Yield % for the fiscal year that ended in Oct. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	11.02	+	0)	/	2.73303
	=	-403.22%

Clearmind Medicine's annualized Total Payout Yield % for the quarter that ended in Jan. 2024 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (0	+	2.45	+	0)	*	4	/	0
	=	N/A%

Clearmind Medicine Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

Clearmind Medicine Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (XCNQ:CMND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (XCNQ:CMND) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

CMND:USA CWY0:Germany

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.